# The evolution of antibiotic resistance

Are we learning the lesson?

- What are antibiotics?
- The problem of antibiotic resistance
- The social economy of antibiotic resistance
- The evolution of resistance
- The ecology of resistance
- Resisting resistance


#### What are antibiotics?

- Antibiotics are a heterogeneous class of molecules that interfere with the growth of bacteria.
- Many antibiotics are naturally occurring, and are isolated from a variety of bacterial, fungal or eukaryotic sources.
- Frequently, naturally occurring antibiotics are modified to make them more effective.
- Some antibiotics are synthetic, and may have no natural counterpart

	Event	Country
1929	penicillin discovered	England
1932	sulfonamides (Prontosil) discovered	Germany
1939	gramicidin discovered	United States
1942	penicillin introduced	England and United States
1943	streptomycin discovered	United States
1943	bacitracin discovered	United States
1945	cephalosporins discovered	Italy
1947	chloramphenicol discovered	United States
1947	chlortetracycline discovered	United States
1949	neomycin discovered	United States
1950	oxytetracycline discovered	United States
1952	erythromycin discovered	United States
1956	vancomycin discovered	United States
1957	kanamycin discovered	Japan
1960	methicillin introduced	. England and United States
1961	ampicillin introduced	England
1961	spectinomycin reported	United States
1963	gentamicin discovered	United States
1964	cephalosporins introduced	England
1966	doxycycline introduced	United States
1967	clindamycin reported	United States
1971	tobramycin discovered	United States
1972	cephamycins (cefoxitin) discovered	United States
1972	minocycline introduced	United States


ï


٦,



#### Mode of action


- Antibiotics work in a variety of ways, but generally depend on their ability to:
- Mimic an critical molecule
- Bind irreversibly to an active site
- Compete with a naturally occurring molecule for binding, passage or transport.






N-acetylglucosamine - N-acetylmuramic acid

## The pentapeptide








Figure5: Comparison of the structures of the D-Ala-D-Alaterminus of the pentapeptide component of the cell wall (left)and amoxicillin (right). As one can see, the two appear very similar.

### The objective


- Antibiotics are designed to slow the growth, or to kill target organisms.
- A therapeutic antibiotic needs to do this with minimal toxicity to the host
- This is usually accomplished by directing the antibiotic at a phylogenetically unique feature of the bacterial target (e.g. cell wall, ribosome, etc...)

- What are antibiotics?
- The problem of antibiotic resistance
- The social economy of antibiotic resistance
- The evolution of resistance
- The ecology of resistance
- Resisting resistance

### The evolutionary effect

- Why are antibiotics naturally occurring?
- Surely not for us to find and refine them
- They play a role in microbial ecosystems (more on this later)
- Important to remember that the selection for resistance does not begin with the discovery of penicillin.

- But it sure gets worse.
- Antibiotic
  resistance
  emerges in
  response to
  antibiotic use.




# Just how important is the problem?

- In terms of public health, one of the central public health issues of our age.
- The problem is simple: every human bacterial pathogen harbors resistance to all currently known antibiotics.

# Emerging antibiotic resistance


- A tremendously important public health problem:
  - 10-50% of incoming infections in clinical settings are resistant to one or more frontline antibiotics.
  - 3 million deaths worldwide due to diarrheacausing infections, most of them antibiotic resistant
  - A prevalent cause of complications or death in immuno-compromised individuals.


#### Emerging Vancomycin-resistant Enterococcal Infections\*




\* in U.S. NNIS Hospitals







#### Some scary stuff




Methycillin resistant *S. aureus* and Vancomycin resistant *Enterococcus* infections S.S. Huang et al, EID **8**(2):195-201

### Multidrug resistance



#### Percent of Isolates



Percent Typhimurium with at least ACSSuT pattern for all sites:


1996 - 103/306 = 34% | 1997 - 115/326 = 35% | 1998 - 120/380 = 32%


1999 - 102/362 = 28% | 2000 - 84/303 = 28%

CA=Alameda, Contra Costa, and San Francisco counties NX=excluding New York City

LX=Los Angeles County NYC=New York City

# A global problem






Source: World Health Organization/VRD


# Why is resistance so rampant?

- Overuse
- •Misuse
- Misprescription
- Environmental hazard



## National Ambulatory Medical Care Survey (USA, 1998)

	N° (mill.) of	Presence (%) of	% treated with
	visits	bacterial pathogens	AB
Rhinitis	25	5	30
Otitis media	13	65	76
Pharyngitis	14	25	62
Bronchitis	13	10	59
Sinusitis	- 11	40	70



#### Use of antibiotics<sup>3</sup>

#### Where antibiotics

are used	Types of use	Questionable use	
Human use (50%)	20% Hospital	- 20-50% Unnecessary	
	80% Community		
Agricultural use (50%)	20% Therapeutic	- 40-80% Highly questionable	
	80% Prophylactic/growth promotion		

### The scope of antibiotic use

- 50 million pounds of antibiotics are produced annually in the US
- 190 million hospital prescriptions/year in the US, 133 million outside prescriptions.
- 50% of the latter category may be unnecessary.